Complete basal cell carcinoma remission with imiquimod in a patient with nevoid basal cell carcinoma syndrome and associated basal cell carcinoma of the scalp and invasive ductal breast cancer

Quist, Sven R; Franke, Ingolf; Helmdach, Marten; Kraus, Cornelia; Reis, André; Froster, Ursula G.; Fehsecke, Dirk; Gollnick, Harald; Bonnekoh, Bernd

doi:10.1016/j.jaad.2009.07.046

Cited by 4 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1 case, it was a PTCH1 mutation carrier with multiple cutaneous tumors and invasive ductal and medullar breast carcinoma, with no mutations in BRCA1 and BRCA2 genes (16). In 1 case, it was a PTCH1 mutation carrier with multiple cutaneous tumors and invasive ductal and medullar breast carcinoma, with no mutations in BRCA1 and BRCA2 genes (16).…”

Section: Brca1 Mutation In a Low-grade Ovarian Carcinomamentioning

confidence: 99%

A Low-grade Ovarian Carcinoma Case With Coincident LOH of PTCH1 and BRCA1, and a Mutation in BRCA1

Maurac

Sabol²,

Musani³

et al. 2012

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

We report a case of a 53-year-old woman with Grade 1 serous cystadenocarcinoma on her left ovary and metastatic serous adenocarcinoma on her right ovary. Serous carcinoma is the most common type of ovarian cancer, representing approximately half of all cases. Because of positive family history, the patient was referred for BRCA1/2 screening. Germline BRCA1 mutation c.676delT (p.C226VfsX8) was found, and in tumor tissue the normal allele was lost. Tumor tissue also had loss of heterozygosity in the PTCH1 gene, one of the major members of the Hedgehog-Gli (Hh-Gli) pathway. Gene expression analysis showed upregulation of the Hh-Gli pathway in both ovaries compared with healthy ovarian tissue. Primary cell culture was developed from the patient's tissue and showed downregulation of gene expression in response to cyclopamine, a Hh-Gli pathway inhibitor. The Hh-Gli signaling pathway may play a role in malignant transformation and metastasis of ovarian cancer.

show abstract

Section: Brca1 Mutation In a Low-grade Ovarian Carcinomamentioning

confidence: 99%

A Low-grade Ovarian Carcinoma Case With Coincident LOH of PTCH1 and BRCA1, and a Mutation in BRCA1

Maurac

Sabol²,

Musani³

et al. 2012

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

show abstract

“…People with certain medical conditions have an increased risk of developing non‐melanoma skin cancers (NMSCs). This is especially the case with lowered immunity , a history of excessive cumulative ultraviolet radiation exposure or with rare inherited skin disorders like nevoid basal cell carcinoma syndrome (NBCCS) or xeroderma pigmentosum . These patients can develop multiple, multifocal cutaneous (pre) malignancies, on often aesthetically delicate areas and are often subject to repeated and ongoing treatments from adolescence onward, offering a challenge to the treatment regime.…”

Section: Introductionmentioning

confidence: 99%

mTHPC mediated, systemic photodynamic therapy (PDT) for nonmelanoma skin cancers: Case and literature review

2015

View full text Add to dashboard Cite

Although mTHPC-PDT is described in the literature as an interesting and promising therapeutic option, especially for multiple NMSCs, a randomized clinical trial is lacking and personal experiences warrant too much skepticism. With the recent introduction of the hedgehog pathway inhibitor vismodegib, mTHPC-PDT seems to be less suitable as a first line of treatment; it should be considered as a last resort therapy.

show abstract

Gorlin (Naevoid Basal Cell Carcinoma) Syndrome

Ong

Farndon

2019

Harper's Textbook of Pediatric Dermatology

View full text Add to dashboard Cite

Complete basal cell carcinoma remission with imiquimod in a patient with nevoid basal cell carcinoma syndrome and associated basal cell carcinoma of the scalp and invasive ductal breast cancer

Cited by 4 publications

References 4 publications

A Low-grade Ovarian Carcinoma Case With Coincident LOH of PTCH1 and BRCA1, and a Mutation in BRCA1

A Low-grade Ovarian Carcinoma Case With Coincident LOH of PTCH1 and BRCA1, and a Mutation in BRCA1

mTHPC mediated, systemic photodynamic therapy (PDT) for nonmelanoma skin cancers: Case and literature review

Gorlin (Naevoid Basal Cell Carcinoma) Syndrome

Contact Info

Product

Resources

About